keyword
MENU ▼
Read by QxMD icon Read
search

multiples myeloma

keyword
https://www.readbyqxmd.com/read/29679038/ninety-minute-daratumumab-infusion-is-safe-in-multiple-myeloma
#1
Hallie Barr, Jessica Dempsey, Allyson Waller, Ying Huang, Nita Williams, Nidhi Sharma, Don M Benson, Ashley E Rosko, Yvonne A Efebera, Craig C Hofmeister
No abstract text is available yet for this article.
March 31, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29678657/development-and-evaluation-of-an-optimal-human-single-chain-variable-fragment-derived-bcma-targeted-car-t-cell-vector
#2
Eric L Smith, Mette Staehr, Reed Masakayan, Ishan J Tatake, Terence J Purdon, Xiuyan Wang, Pei Wang, Hong Liu, Yiyang Xu, Sarah C Garrett-Thomson, Steven C Almo, Isabelle Riviere, Cheng Liu, Renier J Brentjens
B cell maturation antigen (BCMA) has recently been identified as an important multiple myeloma (MM)-specific target for chimeric antigen receptor (CAR) T cell therapy. In CAR T cell therapy targeting CD19 for lymphoma, host immune anti-murine CAR responses limited the efficacy of repeat dosing and possibly long-term persistence. This clinically relevant concern can be addressed by generating a CAR incorporating a human single-chain variable fragment (scFv). We screened a human B cell-derived scFv phage display library and identified a panel of BCMA-specific clones from which human CARs were engineered...
March 28, 2018: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/29678086/implementing-systems-medicine-a-medical-informatics-perspective
#3
Matthias Ganzinger, Matthias Gietzelt, Christian Karmen, Blanca Flores, Petra Knaup
Systems medicine is a paradigm for translating in silico methods developed for modelling biological systems into the field of medicine. Such approaches rely on the integration of as many data sources as possible, both in the dimension of disease knowledge and patient data. This is a challenging task that can only be implemented in clinical routine with the help of suitable information technology from the field of Medical Informatics. For the research project "Clinically-applicable, omics-based assessment of survival, side effects, and targets in multiple myeloma" (CLIOMMICS) we developed a prototypical systems medicine application system...
2018: Studies in Health Technology and Informatics
https://www.readbyqxmd.com/read/29676443/induction-therapy-for-multiple-myeloma-more-is-not-necessarily-better
#4
EDITORIAL
Lalit Kumar, Prasanth Ganesan
No abstract text is available yet for this article.
April 20, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29676376/an-unusual-presentation-of-large-b-cell-lymphoma-with-interferon-regulatory-factor-4-gene-rearrangement
#5
Anuj Verma, Sridhar Epari, Sumeet Gujral, Tanuja Shet
Rearrangements involving interferon regulatory factor 4 (IRF4) gene has been recently described in a subtype of diffuse large B-cell lymphoma (DLBCL). They occur in a typical clinical setting of a pediatric age group, predominantly with tonsillar mass, usually as a low-stage disease and with good response to chemotherapy. Histomorphologically, they show nodular/follicular architecture with diffuse strong immunopositivity for multiple myeloma oncogene 1. Here, the authors describe one such unusual case of large B-cell lymphoma with IRF4 gene rearrangement in a young child with the unusual location of inguinal region and detailed pathological (histological, immunohistochemical, and molecular) findings...
April 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29676004/rapidly-changing-myeloma-epidemiology-in-the-general-population-increased-incidence-older-patients-and-longer-survival
#6
REVIEW
Ingemar Turesson, Magnus Bjorkholm, Cecilie Hveding Blimark, Sigurdur Kristinsson, Ramon Velez, Ola Landgren
The incidence of multiple myeloma is characterized by a steep increase with advancing age. Dramatic improvements in survival have been reported in clinical trials; however, elderly patients are generally underrepresented in these. The aims of this study are to review patterns of incidence and survival in multiple myeloma in the general population. We searched PubMed for population-based studies on trends in incidence and survival published between January 1, 2000 and June 30, 2017 and based on regional or national cancer registries and report the following results of the review...
April 20, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29675792/maintenance-in-myeloma-patients-achieving-complete-response-after-upfront-therapy-a-pooled-analysis
#7
Chiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, Stefano Spada, Francesca Patriarca, Claudia Crippa, Roberto Mina, Tommasina Guglielmelli, Dina Ben-Yehuda, Daniela Oddolo, Chiara Nozzoli, Emanuele Angelucci, Nicola Cascavilla, Rita Rizzi, Stefano Rocco, Luca Baldini, Elena Ponticelli, Magda Marcatti, Clotilde Cangialosi, Tommaso Caravita, Giulia Benevolo, Roberto Ria, Arnon Nagler, Pellegrino Musto, Paola Tacchetti, Paolo Corradini, Massimo Offidani, Antonio Palumbo, Maria Teresa Petrucci, Mario Boccadoro, Francesca Gay
PURPOSE: Maintenance demonstrated to improve survival in newly diagnosed multiple myeloma (NDMM) patients and the achievement of complete response (CR) is a strong predictor of survival. Nevertheless, the role of maintenance according to response after induction/consolidation has not been investigated so far. To evaluate the impact of maintenance according to response, we pooled together and retrospectively analyzed data from 955 NDMM patients enrolled in two trials (GIMEMA-MM-03-05 and RV-MM-PI-209)...
April 19, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29674643/diagnostic-thresholds-for-free-light-chains-in-multiple-myeloma-depend-on-the-assay-used
#8
Xavier Bossuyt, Michel Delforge, Martin Reynders, Doreen Dillaerts, Ben Sprangers, Karel Fostier, Koen Poesen, Martine Vercammen
No abstract text is available yet for this article.
April 20, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29674494/safety-and-efficacy-of-vorinostat-bortezomib-doxorubicin-and-dexamethasone-in-a-phase-i-ii-study-for-relapsed-or-refractory-multiple-myeloma-verumm-study-vorinostat-in-elderly-relapsed-and-unfit-multiple-myeloma
#9
Johannes M Waldschmidt, Alexander Keller, Gabriele Ihorst, Olga Grishina, Stefan Müller, Dagmar Wider, Anna V Frey, Kristina King, Roman Simon, Annette May, Pierfrancesco Tassone, Justus Duyster, Manfred Jung, Noopur Raje, Ralph Wäsch, Monika Engelhardt
This phase I/II trial was conducted to investigate the safety, efficacy, and pharmacodynamics of the pan-HDAC-inhibitor (HDACi) vorinostat combined with bortezomib, doxorubicin, and dexamethasone (VBDD) in patients suffering from relapsed/refractory multiple myeloma (RRMM). In the phase I part of this study, 9/33 patients received dose-escalated vorinostat (100, 200, 300mg), using a 4-day-on and 4-day-off schedule, and a standard 3+3 design. In the phase II part of the study, 24/33 patients were included to further assess VBDD's safety and efficacy...
April 19, 2018: Haematologica
https://www.readbyqxmd.com/read/29673407/hypercalcemia-as-a-rare-presentation-of-angioimmunoblastic-t-cell-lymphoma-a-case-report
#10
Sana Chams, Inaya Hajj Hussein, Skye El Sayegh, Nour Chams, Khalid Zakaria
BACKGROUND: Angioimmunoblastic T cell lymphoma is a rare malignancy, accounting for only 2% of all non-Hodgkin lymphomas, first described in the 1970s and subsequently accepted as a distinct entity in the current World Health Organization classification. Due to the paucity of this disease, there is still no identifiable etiology, no consistent risk factors, and the pathogenesis remains unclear. CASE PRESENTATION: An 83-year-old Caucasian man presented to an emergency department with palpitations and was found to have atrial fibrillation...
April 20, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29673108/lenalidomide-versus-lenalidomide-dexamethasone-prolonged-treatment-after-second-line-lenalidomide-dexamethasone-induction-in-multiple-myeloma
#11
Johan Lund, Astrid Gruber, Birgitta Lauri, Adil Doganay Duru, Cecilie Blimark, Agneta Swedin, Markus Hansson, Karin Forsberg, Lucia Ahlberg, Conny Carlsson, Anders Waage, Peter Gimsing, Annette Juul Vangsted, Ulf Frølund, Erik Holmberg, Gösta Gahrton, Evren Alici, Mats Hardling, Ulf-Henrik Mellqvist, Hareth Nahi
Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single-agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an initial response to Len+Dex induction. Patients with RRMM who responded to first-line Len+Dex in an observational study (NCT01430546) received up to 24 cycles of either Len (25 mg/day) or Len+Dex (25 mg/day and 40 mg/week) as prolonged treatment in a subsequent phase 2 clinical trial (NCT01450215)...
April 19, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29672885/use-of-depth-of-response-to-predict-progression-free-survival-in-relapsed-or-refractory-multiple-myeloma-evaluation-of-results-from-102-clinical-trials
#12
Naveen Mangal, Ahmed Hamed Salem, Rajeev M Menon, Kevin J Freise
Progression-free survival (PFS) is the standard endpoint for demonstration of clinical effectiveness of novel therapies in relapsed or refractory multiple myeloma (RRMM). However, the long evaluation times for PFS limits its usefulness in the development of new therapies. Therefore, the objective of this analysis was to determine the relationship between response rates and median PFS in RRMM. A database was systematically developed from 268 identified RRMM trials reported from 1999 to 2016. Evaluated covariates for the relationship between response rates and PFS included age, sex, drug class(es), and number of drug classes...
April 19, 2018: Hematological Oncology
https://www.readbyqxmd.com/read/29671785/activation-of-er-stress-dependent-mir-216b-has-a-critical-role-in-salvia-miltiorrhiza-ethanol-extract-induced-apoptosis-in-u266-and-u937-cells
#13
Changmin Kim, Hyo-Sook Song, Hojung Park, Bonglee Kim
Although Salvia miltiorrhiza has been reported to have anti-cancer mechanisms, such as caspase activation, cell cycle arrest, an anti-angiogenesis effect, and Bcl-2 family regulation, its underlying mechanism of endoplasmic reticulum (ER) stress-mediated apoptosis has never been demonstrated. Thus, in this current study, ER stress-related apoptosis via miR-216b of the ethanol extract of Salvia miltiorrhiza (SM) is elucidated for the first time. SM treatment inhibited the viability of U266 and U937 cells in a concentration-dependent manner...
April 19, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29671193/diagnostic-performance-of-18-f-fdg-pet-ct-and-whole-body-mri-before-and-early-after-treatment-of-multiple-myeloma-a-prospective-comparative-study
#14
Mohammad Abd Alkhalik Basha, Maged Abdel Gelil Hamed, Rania Refaat, Mohamad Zakarya AlAzzazy, Manar A Bessar, Elshaimaa Mohamed Mohamed, Ayman F Ahmed, Heba Fathy Tantawy, Khaled Mohamed Altaher, Ahmed Ali Obaya, Amira Hamed Mohamed Afifi
OBJECTIVE: To determine the diagnostic accuracy of WB-MRI and 18 F-FDG PET/CT in detecting infiltration pattern, disease activity, and response to treatment in patients with multiple myeloma (MM). MATERIALS AND METHODS: Fifty-six patients with confirmed MM were included in the present study for pre-treatment evaluation. Among these individuals, 22 patients were available for the post-treatment evaluation of response to therapy. All patients were imaged with both WB-MRI and 18 F-FDG PET/CT...
April 18, 2018: Japanese Journal of Radiology
https://www.readbyqxmd.com/read/29670315/carfilzomib-for-multiple-myeloma
#15
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
April 2018: Australian Prescriber
https://www.readbyqxmd.com/read/29669947/anti-cd19-car-t-cells-with-high-dose-melphalan-and-autologous-stem-cell-transplantation-for-refractory-multiple-myeloma
#16
Alfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, Simon F Lacey, Jan Joseph Melenhorst, Maria Krevvata, Martin P Carroll, William H Matsui, Qiuju Wang, Madhav V Dhodapkar, Kavita Dhodapkar, Rituparna Das, Dan T Vogl, Brendan M Weiss, Adam D Cohen, Patricia A Mangan, Emily C Ayers, Selene Nunez-Cruz, Irina Kulikovskaya, Megan M Davis, Anne Lamontagne, Karen Dengel, Naseem Ds Kerr, Regina M Young, Donald L Siegel, Bruce L Levine, Michael C Milone, Marcela V Maus, Carl H June
BACKGROUND: Multiple myeloma is usually fatal due to serial relapses that become progressively refractory to therapy. CD19 is typically absent on the dominant multiple myeloma cell population but may be present on minor subsets with unique myeloma-propagating properties. To target myeloma-propagating cells, we clinically evaluated autologous T cells transduced with a chimeric antigen receptor (CAR) against CD19 (CTL019). METHODS: Subjects received CTL019 following salvage high-dose melphalan and autologous stem cell transplantation (ASCT)...
April 19, 2018: JCI Insight
https://www.readbyqxmd.com/read/29669929/antigen-mediated-regulation-in-monoclonal-gammopathies-and-myeloma
#17
Shiny Nair, Joel Sng, Chandra Sekhar Boddupalli, Anja Seckinger, Marta Chesi, Mariateresa Fulciniti, Lin Zhang, Navin Rauniyar, Michael Lopez, Natalia Neparidze, Terri Parker, Nikhil C Munshi, Rachael Sexton, Bart Barlogie, Robert Orlowski, Leif Bergsagel, Dirk Hose, Richard A Flavell, Pramod K Mistry, Eric Meffre, Madhav V Dhodapkar
A role for antigen-driven stimulation has been proposed in the pathogenesis of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) based largely on the binding properties of monoclonal Ig. However, insights into antigen binding to clonal B cell receptors and in vivo responsiveness of the malignant clone to antigen-mediated stimulation are needed to understand the role of antigenic stimulation in tumor growth. Lysolipid-reactive clonal Ig were detected in Gaucher disease (GD) and some sporadic gammopathies...
April 19, 2018: JCI Insight
https://www.readbyqxmd.com/read/29667176/pre-diagnostic-blood-immune-markers-incidence-and-progression-of-b-cell-lymphoma-and-multiple-myeloma-univariate-and-functionally-informed-multivariate-analyses
#18
Roel Vermeulen, Fatemeh Saberi Hosnijeh, Barbara Bodinier, Lützen Portengen, Benoît Liquet, Javiera Garrido-Manriquez, Henk Lokhorst, Ingvar A Bergdahl, Soterios A Kyrtopoulos, Ann-Sofie Johansson, Panagiotis Georgiadis, Beatrice Melin, Domenico Palli, Vittorio Krogh, Salvatore Panico, Carlotta Sacerdote, Rosario Tumino, Paolo Vineis, Raphaële Castagné, Marc Chadeau-Hyam
Recent prospective studies have shown that dysregulation of the immune system may precede the development of B-cell lymphomas (BCL) in immunocompetent individuals. However, to date, the studies were restricted to a few immune markers, which were considered separately. Using a nested case-control study within two European prospective cohorts, we measured plasma levels of 28 immune markers in samples collected a median of 6 years prior to diagnosis (range, 2.01-15.97) in 268 incident cases of BCL (including multiple myeloma) and matched controls...
April 18, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29667156/how-we-manage-patients-with-plasmacytomas
#19
REVIEW
Despina Fotiou, Meletios A Dimopoulos, Efstathios Kastritis
PURPOSE OF REVIEW: To discuss the diagnostic approach, treatment options, and future considerations in the management of plasmacytomas, either solitary or in the context of overt multiple myeloma (MM). RECENT FINDINGS: Advanced imaging techniques such as whole-body magnetic resonance imaging and positron emission tomography/computerized tomography are essential for the diagnostic workup of solitary plasmacytomas (SP) to rule out the presence of other disease foci...
April 17, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29666962/activity-of-indatuximab-ravtansine-against-triple-negative-breast-cancer-in-preclinical-tumor-models
#20
Kurt Schönfeld, Peter Herbener, Chantal Zuber, Thomas Häder, Katrin Bernöster, Christoph Uherek, Jörg Schüttrumpf
PURPOSE: Triple-negative breast cancer (TNBC) is related with a poor prognosis as patients do hardly benefit from approved therapies. CD138 (Syndecan-1) is upregulated on human breast cancers. Indatuximab ravtansine (BT062) is an antibody-drug-conjugate that specifically targets CD138-expressing cells and has previously shown clinical activity in multiple myeloma. Here we show indatuximab ravtansine as a potential mono- and combination therapy for TNBC. METHODS: The effects of indatuximab ravtansine were assessed in vitro in SK-BR-3 and T47D breast cancer cell lines...
April 17, 2018: Pharmaceutical Research
keyword
keyword
61997
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"